# **Special Issue**

# New Advances of Biomedical Engineering and Materials

## Message from the Guest Editors

In recent years, tremendous progress has been made in biomedical engineering and materials including drug delivery systems, minimal invasive surgery, tissue regeneration, and biocompatible materials. With the rapid development of Al. cell therapy, tissue engineering, and their integration into modern medical science, biomedical engineering, and materials are entering a new era. Scenarios that were originally only seen in movie scenes, such as artificial organ transplantation, cyborgs, automatic tissue repair, and regeneration, etc., are now no longer just imagination, but closer to reality. We need innovative ideas and new technologies that can be incorporated into the field of biomedical engineering and materials so disease diagnosis and treatment can be more effective, and subsequently, a better health care system can be accomplished. Therefore, I would like to invite our colleagues to submit original research and review articles for this Special Issue. I hope the future of biomedical engineering and materials is bright and promising.

#### **Guest Editors**

Dr. Mei-Jung Chen

Dr. Yaw Sing Tan

Prof. Dr. Chuan Li

# Deadline for manuscript submissions

30 June 2026



an Open Access Journal by MDPI

Impact Factor 3.9 CiteScore 6.8 Indexed in PubMed



mdpi.com/si/261967

Biomedicines
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
biomedicines@mdpi.com

mdpi.com/journal/biomedicines





an Open Access Journal by MDPI

Impact Factor 3.9 CiteScore 6.8 Indexed in PubMed





# **About the Journal**

## Message from the Editor-in-Chief

Biomedicines (ISSN 2227-9059) is an open access iournal devoted to all aspects of research on human health and disease, the discovery and characterization of new therapeutic targets, therapeutic strategies, and research of naturally driven biomedicines, pharmaceuticals, and biopharmaceutical products. Topics include pathogenesis mechanisms of diseases, translational medical research, biomaterial in biomedical research, natural bioactive molecules, biologics, vaccines, gene therapies, cell-based therapies, targeted specific antibodies, recombinant therapeutic proteins, nanobiotechnology driven products, targeted therapy, bioimaging, biosensors, biomarkers, and biosimilars. The journal is open for publication of studies conducted at the basic science and preclinical research levels. We invite you to consider submitting your work to Biomedicines, be it original research, review articles, or developing Special Issues of current key topics.

#### Editor-in-Chief

#### Prof. Dr. Felipe Fregni

- Neuromodulation Center and Center for Clinical Research Learning, Spaulding Rehabilitation Hospital and Massachusetts General Hospital, Harvard Medical School, Boston, MA 02114, USA
- 2. Department of Epidemiology, Harvard T.H. Chan School of Public Health, Boston, MA 02115, USA

#### **Author Benefits**

#### **High Visibility:**

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, CAPlus / SciFinder, and other databases.

### Journal Rank:

JCR - Q1 (Pharmacology and Pharmacy) / CiteScore - Q1 (Medicine (miscellaneous))

#### **Rapid Publication:**

manuscripts are peer-reviewed and a first decision is provided to authors approximately 17 days after submission; acceptance to publication is undertaken in 2.9 days (median values for papers published in this journal in the first half of 2025).